PharmaIN reports Phase 1 multiple-dose PHIN-214 findings in cirrhosis
Company / institutional announcement · PharmaIN Corporation
Source published: · Event / reporting date: 2026-11-05
Site published: 2026-11-07 · Updated: 2026-11-07
This source is linked automatically. Choose a question to get started.
What changed
On November 5, PharmaIN reported conference findings from PHIN-001: 12 participants with Child-Pugh B cirrhosis received PHIN-214; 10 completed 28 days. The issuer described Grade 1–2 treatment-related adverse events and exploratory renal, hemodynamic and PK findings. The ongoing small Phase 1 study does not establish clinical benefit. This is a company conference announcement, not a peer-reviewed paper.
Why it may matter
Analysis: Relevant to repeated-dose PK/PD and portal-hypertension development; larger studies, appropriate controls and further safety follow-up remain necessary.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections